This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Santa Clara, CA-based Agilent Technologies, Inc. was originally a spin-off from Hewlett-Packard. The company is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG). The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers’ representatives, telesales and electronic commerce.
Wall Street Tumbles Following Yield Curve Inversion
by Zacks Equity Research
Wall Street Tumbles Following Yield Curve Inversion
Stock Futures Plunge as Recession Fears Intensify
by Zacks Equity Research
U.S. stock futures plummeted ahead of trading on Wednesday after a key Treasury yield curve inverted signaling an impending recession.
Agilent (A) Gears Up for Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Agilent's (A) leadership position and strength in revenue segments are likely to aid fiscal third-quarter 2019 results.
Agilent Technologies (A) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Truth About Market Timing - July 30, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Agilent to Acquire BioTek, Cell Analysis Portfolio to Expand
by Zacks Equity Research
Agilent Technologies (A) enters into an agreement to buy BioTek Instruments, which is likely to strengthen its cell analysis capabilities and expand presence in life science research space.
5 Top & Flop ETF Areas of Q2
by Sanghamitra Saha
Dovish Fed comments and chances of U.S.-China trade truce kept the market steady in the second quarter. These ETF areas won and lost in the second quarter.
Electronics Testing Equipment Industry Outlook Appears Bright
by Shilpa Mete
Prospects of the Electronics - Testing Equipment industry look bright, thanks to the increasing proliferation of electronic devices in every major sector.
Agilent Announces Receipt of FDA Approval for pharmDX Assay
by Zacks Equity Research
Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
Why Is Agilent (A) Up 3.9% Since Last Earnings Report?
by Zacks Equity Research
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.